ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial A phase 3, multicenter, randomized, open-label, parallel-group study of the efficacy and safety of lenalidomide (Revlimid) versus chlorambucil as first-line therapy for previously untreated elderly patients with B-cell chronic lymphocytic leukemia (the origin trial)
EudraCT number 2008-003079-32
Protocol number CC-5013-CLL-008
Sponsor Celgene Corporation
Indications Oncology
Diagnosis B-cell chronic lymphocytic leukemia
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2009
Date of approval by Institute (SÚKL) 14.9.2009; prodlouž.13.8.2010 +11.8.2011
Date of approval by EC 4.4.2013
Date of initiation CT in ČR 24.1.2012
Date of ending CT in ČR 20.7.2018 (23.4.2018)
Sites Fakultní nemocnice Hradec Králové, 2. Interní klinika - oddělení klinické hematologie, Sokolská 581, 500 05 Hradec Králové
FNKV, Oddělení klinické hematologie, Šrobárova 50, 100 34 Praha 10 (discontinued)
Ústav klinické hematologie, FN Ostrava (discontinued)

‹‹ Back to list